Detection method of alendronate sodium tablet related substances
Optimizing chromatographic conditions through high performance liquid chromatography, the problems of low detection accuracy and impurities interference in the detection of alendronate sodium tablets were solved, and higher detection accuracy and resolution were achieved, ensuring the safety of drug quality.
Patent Information
- Application Number
- CN202310781787.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-29
- Publication Date
- 2024-12-03
AI Technical Summary
Among the existing alendronate sodium tablet detection methods, the thin layer chromatography in the Chinese Pharmacopoeia has low detection accuracy and poor accuracy, and there are interferences in the detection of impurities in foreign Pharmacopoeia methods, which leads to difficulties in drug quality control and affects drug safety.
Using high performance liquid chromatography, using specific chromatographic columns, mobile phases and detection wavelength settings, combined with the ratio of sodium citrate buffer and acetonitrile, optimized chromatographic conditions to improve the resolution and detection accuracy of impurities, using Shimadzu LC -2030C-PLUS liquid chromatograph and Hamilton PRP-1 chromatogram column, mobile phase A is a mixture of sodium citrate buffer and acetonitrile, mobile phase B is acetonitrile, flow rate is 1.0ml/min, column temperature is 30℃, The detection wavelength was 266 nm, the injection volume was 15 μl, and the diluent was 0.1 mol/L sodium citrate solution. The determination was performed by external standard method.
The separation of impurity A and the baseline fluctuations between the peaks of the auxiliary material are significantly improved, the accuracy, sensitivity and stability of the detection are improved, impurity interference is reduced, and the reliability of the quality of the drug is ensured.
Smart Images

Figure CN119064484A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of drug detection and relates to a method for detecting related substances of alendronate sodium tablets. Background Art
[0002] The main ingredient of alendronate sodium tablets is alendronate sodium. At the cellular level, alendronate sodium has a tropism for bone resorption sites, especially sites where osteoclasts act. Normally, osteoclasts adhere to the bone surface but do not have rough edges, which is a sign of active bone resorption. Alendronate sodium does not affect the aggregation or adhesion of osteoclasts, but it does inhibit the activity of osteoclasts. Alendronate sodium must be taken continuously to inhibit the formation of newly formed osteoclasts located on the resorbing surface. Histomorphometry in baboons and rats showed that alendronate sodium can reduce bone turnover (i.e., the number of bone remodeling sites), and at these remodeling sites, bone formation exceeds bone resorption, resulting in a gradual increase in bone mass.
[0003] The control of related substances of products is crucial to product quality control. Among the current detection methods for related substances of alendronate sodium tablets, the detection method included in the Chinese Pharmacopoeia is thin layer chromatography, which has low detection precision and poor accuracy. The detection methods of related substances included in other foreign pharmacopoeias are the same, but after the inventor's method was reproduced, it was found that there was interference in the detection of known impurities in the foreign pharmacopoeia methods. In order to ensure the quality of the preparation during research, production, storage, sales and use, and to ensure the safety and effectiveness of the drug, it is urgent to provide a detection method with high sensitivity and good separation between impurities. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a method for detecting related substances in alendronate sodium tablets. The chromatographic conditions described in the present invention are compared with the standard chromatographic conditions provided in the European Pharmacopoeia, and the interference of known impurities is improved compared with the original chromatographic conditions.
[0005] The known impurities that alendronate sodium may contain in the final product are as follows:
[0006]
[0007] A method for detecting related substances in alendronate sodium tablets comprises the following steps:
[0008] High performance liquid chromatography was used to quantitatively detect the related substances in alendronate sodium tablets;
[0009] HPLC conditions included:
[0010] Chromatographic column: Chromatographic column with styrene divinylbenzene copolymer as filler;
[0011] Mobile phase A: sodium citrate buffer (14.7 g of sodium citrate was added to 1000 ml of water and the pH was adjusted to 4.5 with hydrochloric acid solution)-acetonitrile (75:25, v / v);
[0012] Mobile phase B: acetonitrile;
[0013] Flow rate: 1.0ml / min;
[0014] Column temperature: 30°C;
[0015] Detection wavelength: 266nm;
[0016] The injection volume was 15 μl;
[0017] Diluent: 0.1 mol / L sodium citrate solution.
[0018] Further, the elution procedure is as follows:
[0019]
[0020] Furthermore, the related substance is 4-hydroxybenzoic acid.
[0021] Further, the test solution and the system suitability solution are respectively injected into the liquid chromatograph, and the chromatogram is recorded. The preparation method of the reference solution and the test solution is as follows:
[0022] Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing about 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml, accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference substance solution.
[0023] Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), put them in a 100 ml volumetric flask, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and put it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0024] Furthermore, the color spectrum is recorded, and the content of known impurities is calculated by using the external standard method; the content of other single impurities is calculated by using the main component external standard method.
[0025] Furthermore, the calculation method of known impurities and other individual impurities is:
[0026] % of known impurities = (impurity peak area in the test sample × concentration of impurities in the reference sample) / (impurity peak area in the reference sample × concentration of alendronic acid in the test sample) × 100%;
[0027] Other single impurities % = (other single impurity peak area in the test sample × alendronic acid concentration in the reference sample) / (alendronic acid peak area in the reference sample × alendronic acid concentration in the test sample) × 100%.
[0028] Furthermore, the temperature of the sample injection plate is 5°C.
[0029] A method for detecting related substances in alendronate sodium tablets comprises the following steps:
[0030] (1) Solution preparation:
[0031] Solvent: 0.1 mol / L sodium citrate solution;
[0032] Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing about 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml, accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference substance solution.
[0033] Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place them in a 100 ml volumetric flask, add 0.1 mol / L sodium citrate solution as solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let cool, dilute to scale with 0.1 mol / L sodium citrate solution, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution;
[0034] (2) Chromatographic conditions:
[0035] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0036] Chromatographic column: Hamilton PRP-1 (250*4.1mm, 10μm);
[0037] Mobile phase A: sodium citrate buffer (14.7 g of sodium citrate was added to 1000 ml of water and the pH was adjusted to 4.5 with hydrochloric acid solution)-acetonitrile (75:25);
[0038] Mobile phase B: acetonitrile;
[0039] Flow rate: 1.0ml / min;
[0040] Column temperature: 30°C;
[0041] Detection wavelength: 266nm;
[0042] The injection volume was 15 μl;
[0043] The elution procedure is as follows:
[0044]
[0045] (3) Determination: Take 15 μl of the test solution and system suitability solution respectively, inject them into the liquid chromatograph, and record the chromatogram.
[0046] Beneficial Effects
[0047] Compared with other standard chromatographic conditions, the chromatographic conditions provided by the present invention have improved separation of impurity A and auxiliary material peaks and baseline fluctuations, and have improved accuracy, sensitivity and stability compared with the original chromatographic conditions. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1 Chromatogram of the reference solution for detection method 1;
[0049] Figure 2 It is the chromatogram of the reference solution under the detection method two chromatographic conditions;
[0050] Figure 3 Chromatogram of the reference solution under the chromatographic conditions of the detection method III;
[0051] Figure 4 The blank solution chromatogram under the chromatographic conditions of detection method IV;
[0052] Figure 5 Chromatogram of blank auxiliary material solution under the chromatographic conditions of detection method IV;
[0053] Figure 6 The chromatogram of the reference solution under the chromatographic conditions of detection method IV;
[0054] Figure 7 This is the chromatogram of the test sample solution under the chromatographic conditions of detection method four. DETAILED DESCRIPTION
[0055] Example 1
[0056] Detection method 1 for related substances in alendronate sodium tablets:
[0057] (1) Solution preparation:
[0058] Solvent: 0.1 mol / L sodium citrate solution;
[0059] Reference solution: Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing approximately 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml; accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference solution.
[0060] Blank excipient solution: Take an appropriate amount of blank excipient, add solvent, mechanically shake for 30 minutes, ultrasonicate for 5 minutes, dilute to the scale with solvent, shake well, centrifuge, accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add borax solution (19g→1L) 5 ml and acetonitrile 5 ml respectively; add 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml) 5 ml, shake for 45 seconds, let stand at room temperature for 30 minutes, add dichloromethane 20 ml, shake for 60 seconds, centrifuge, and take the supernatant as the blank excipient solution.
[0061] (2) Chromatographic conditions:
[0062] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0063] Chromatographic column: Hamilton PRP-1 (250*4.1mm, 10μm);
[0064] Mobile phase A: buffer (2.94 g of sodium citrate and 1.42 g of disodium hydrogen phosphate were added to 900 ml of water, pH was adjusted to 8.0 with phosphoric acid, and then water was added to 1000 ml)-acetonitrile (850:150);
[0065] Mobile phase B: buffer (2.94 g of sodium citrate and 1.42 g of disodium hydrogen phosphate were added to 900 ml of water, pH was adjusted to 8.0 with phosphoric acid, and then water was added to 1000 ml)-acetonitrile (700:300);
[0066] Flow rate: 1.0ml / min;
[0067] Column temperature: 45°C;
[0068] Detection wavelength: 266nm;
[0069] The injection volume was 20 μl;
[0070] The elution procedure is as follows:
[0071] Table 1
[0072]
[0073] (3) Determination: Take 20 μl of blank solution and reference solution respectively and inject them into liquid chromatograph. Record the chromatogram. Typical spectra are shown in Figure 1 .
[0074] (4) Results: Figure 1 It can be seen from the spectrum that there is interference at the retention time of impurity A, and the chromatographic conditions are optimized by changing the gradient.
[0075] Example 2
[0076] Method 2 for detecting related substances in alendronate sodium tablets:
[0077] (1) Solution preparation: the same as that in Example 1.
[0078] (2) Chromatographic conditions: The chromatographic conditions are the same as those in Example 1 except that the elution gradient is as follows.
[0079] The elution procedure is as follows:
[0080] Table 2
[0081]
[0082] (3) Determination: Take 20 μl of the test solution and the reference solution respectively and inject them into the liquid chromatograph. Record the chromatogram. The typical spectrum is shown in Figure 2 .
[0083] (4) Results: From the spectrum, it can be seen that the detection of impurity A still interferes. Change the mobile phase system and continue the investigation
[0084] Example 3
[0085] Detection method three for related substances in alendronate sodium tablets:
[0086] (1) Solution preparation:
[0087] Solvent: 0.1 mol / L sodium citrate solution;
[0088] Test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place it in a 100 ml volumetric flask, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0089] Reference solution: Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing approximately 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml; accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference solution.
[0090] Blank excipient solution: Take an appropriate amount of blank excipient, add solvent, mechanically shake for 30 minutes, ultrasonicate for 5 minutes, dilute to the scale with solvent, shake well, centrifuge, accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add borax solution (19g→1L) 5 ml and acetonitrile 5 ml respectively; add 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml) 5 ml, shake for 45 seconds, let stand at room temperature for 30 minutes, add dichloromethane 20 ml, shake for 60 seconds, centrifuge, and take the supernatant as the blank excipient solution.
[0091] (2) Chromatographic conditions:
[0092] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0093] Chromatographic column: Hamilton PRP-1 (250*4.1mm, 10μm);
[0094] Mobile phase A: buffer (14.7 g of sodium citrate was added to 1000 ml of water and the pH was adjusted to 4.5 with hydrochloric acid solution)-acetonitrile (75:25);
[0095] Mobile phase B: acetonitrile;
[0096] Flow rate: 1.0ml / min;
[0097] Column temperature: 30°C;
[0098] Detection wavelength: 266nm;
[0099] The injection volume was 15 μl;
[0100] Sample plate temperature: 5°C
[0101] The elution procedure is as follows:
[0102] Table 3
[0103]
[0104] (3) Determination: Inject blank, blank excipient, test sample and reference sample solutions into a liquid chromatograph and record the chromatogram. Typical spectra are shown in Figure 3 .
[0105] (4) Results: From the spectrum, it can be seen that the blank solvent and blank excipients have no interference with the detection of impurity A. However, impurity A is close to the adjacent peak, so the gradient was changed to continue the investigation.
[0106] Example 4
[0107] Method 4 for detecting related substances in alendronate sodium tablets:
[0108] (1) Solution preparation:
[0109] Solvent: 0.1 mol / L sodium citrate solution;
[0110] Test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place it in a 100 ml volumetric flask, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0111] Reference solution: Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing approximately 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml; accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference solution.
[0112] Blank excipient solution: Take an appropriate amount of blank excipient, add solvent, mechanically shake for 30 minutes, ultrasonicate for 5 minutes, dilute to the scale with solvent, shake well, centrifuge, accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add borax solution (19g→1L) 5 ml and acetonitrile 5 ml respectively; add 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml) 5 ml, shake for 45 seconds, let stand at room temperature for 30 minutes, add dichloromethane 20 ml, shake for 60 seconds, centrifuge, and take the supernatant as the blank excipient solution.
[0113] (3) Chromatographic conditions:
[0114] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0115] Chromatographic column: Hamilton PRP-1 (250*4.1mm, 10μm);
[0116] Mobile phase A: buffer (14.7 g of sodium citrate was added to 1000 ml of water and the pH was adjusted to 4.5 with hydrochloric acid solution)-acetonitrile (75:25);
[0117] Mobile phase B: acetonitrile;
[0118] Flow rate: 1.0ml / min;
[0119] Column temperature: 30°C;
[0120] Detection wavelength: 266nm;
[0121] The injection volume was 15 μl;
[0122] Sample plate temperature: 5°C
[0123] The elution procedure is as follows:
[0124] Table 4
[0125]
[0126] (3) Determination: Inject blank, blank excipient, test sample and reference sample solutions into a liquid chromatograph and record the chromatogram. Typical spectra are shown in Figures 4 to 7 .
[0127] (4) Results: It can be seen from the spectrum that the blank solvent and blank excipients have no interference with the detection of impurity A. Impurity A was not detected in the test solution, and the specificity is good.
[0128] Example 5
[0129] Method 4 for testing the stability of solutions of related substances of alendronate sodium tablets:
[0130] (1) Solution preparation:
[0131] Reference solution: Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing approximately 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml; accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference solution.
[0132] Test sample spiked solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to about 60 mg of alendronic acid), place it in a 100 ml volumetric flask, add an appropriate amount of impurity A reference substance, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, cool, dilute to the scale with solvent, shake well, filter, the solution contains about 3 μg of impurity A per 1 ml, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test sample solution.
[0133] Chromatographic conditions: same as Example 4.
[0134] Determination: Accurately measure the reference solution and the test sample spiked solution and inject them into the liquid chromatograph at 0h, 2h, 4h, 8h, 24h, 16h and 20h respectively, and record the chromatogram.
[0135] result:
[0136] Table 5 Results of stability study of reference solution
[0137]
[0138]
[0139] Table 6 Results of stability study of spiked solutions
[0140]
[0141] For the reference solution, when the sample plate is kept at a temperature of 5°C, the degradation rate of impurity A is within 10%, the degradation rate of the main component is within 2%, and the degradation rate of the test sample spiked solution is within 2%. The reference solution and the test sample spiked solution are stable for 24 hours when the sample plate is kept at a temperature of 5°C.
[0142] Example 6
[0143] Forced degradation experiment of alendronate sodium tablets:
[0144] (1) Solution preparation:
[0145] Undamaged test solution: Test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place them in a 100 ml volumetric flask, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0146] Acid-destroyed test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place them in a 100 ml volumetric flask, add 3 ml of 0.1 mol / L hydrochloric acid solution, destroy them in a water bath at 80°C for 5 hours, add 3 ml of 0.1 mol / L sodium hydroxide solution to neutralize them, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0147] Alkali-destroyed test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place them in a 100 ml volumetric flask, add 3 ml of 0.1 mol / L sodium hydroxide solution, destroy them in a water bath at 80°C for 2 hours, add 3 ml of 0.1 mol / L hydrochloric acid solution to neutralize them, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution.
[0148] Oxidatively damaged test solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to 60 mg of alendronic acid), place them in a 100 ml volumetric flask, add 3 ml of 10% hydrogen peroxide solution, let it stand at room temperature for 30 minutes, then add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, let it cool, dilute to the scale with solvent, shake well, filter, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test solution. High temperature destruction (solid): Take 5 pieces and weigh them accurately, place them in a 50ml volumetric flask, place them at 60℃ for 10 days, add 20% acetonitrile solution and ultrasonicate for 30 minutes to dilute to the scale, mix well, centrifuge and take the supernatant.
[0149] (2) Chromatographic conditions: same as in Example 4.
[0150] (3) Determination: Take a quantity of each of the above solutions and inject them into a liquid chromatograph. Record the chromatogram. The data are shown in Table 7 below.
[0151] Table 7 Forced degradation test data
[0152] Destruction conditions Undamaged (%) Acid damage (%) Alkali damage (%) Oxidative damage (%) Main peak area 12336782 12145936 11248953 12083209 Impurity A / / / / Other single impurities / / / / Total peak area 12336782 12145936 11248953 12083209 Material conservation% / 98.99 90.98 97.66 Peak purity 1.00000 1.00000 1.00000 1.00000
[0153] (4) Results: As can be seen from the above table, after acid, alkali and oxidation, the main peak purity of alendronate sodium tablets was 1.00, and no other impurities were produced by degradation.
[0154] Under the conditions of acid, alkali, oxidation, high temperature and light destruction, the separation between each impurity and the main peak meets the requirements, and the material is basically conserved, indicating that this method can effectively detect various degradation impurities.
[0155] Example 7
[0156] Durability test of related substances of alendronate sodium tablets:
[0157] (1) Solution preparation:
[0158] Reference solution: Accurately weigh appropriate amounts of impurity A and alendronate sodium reference substance, add 0.1 mol / L sodium citrate solution to dissolve and dilute to make a solution containing approximately 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml; accurately measure 5 ml and place in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the reference solution.
[0159] Test sample spiked solution: Take 10 tablets of this product, grind them into powder, accurately weigh an appropriate amount (equivalent to about 60 mg of alendronic acid), place it in a 100 ml volumetric flask, add an appropriate amount of impurity A reference substance, add an appropriate amount of solvent, shake for 30 minutes, ultrasonicate for 5 minutes, cool, dilute to the scale with solvent, shake well, filter, the solution contains about 3 μg of impurity A per 1 ml, take the filtrate, accurately measure 5 ml and place it in a 50 ml polypropylene centrifuge tube; add 5 ml of borax solution (19 g → 1 L) and 5 ml of acetonitrile respectively; add 5 ml of 9-fluorenylmethyl chloroformate acetonitrile solution (freshly prepared before use, concentration 4 mg / ml), shake for 45 seconds, let it stand at room temperature for 30 minutes, add 20 ml of dichloromethane, shake for 60 seconds, centrifuge, and take the supernatant as the test sample solution.
[0160] (2) Chromatographic conditions:
[0161] Original chromatographic conditions: Instrument: Shimadzu LC-2030C-PLUS; Detector: UV
[0162] Chromatographic column: Hamilton PRP-1 (250*4.1mm, 10μm);
[0163] Mobile phase A: buffer (14.7 g of sodium citrate was added to 1000 ml of water and the pH was adjusted to 4.5 with hydrochloric acid solution)-acetonitrile (75:25);
[0164] Mobile phase B: acetonitrile;
[0165] Flow rate: 1.0ml / min;
[0166] Column temperature: 30°C;
[0167] Detection wavelength: 266nm;
[0168] The injection volume was 15 μl;
[0169] Sample plate temperature: 5°C
[0170] The elution procedure is as follows:
[0171] Table 8
[0172]
[0173] The parameters are changed as follows:
[0174] (1) Change the flow rate, other conditions remain unchanged:
[0175] ①0.9ml / min; ②1.1ml / min
[0176] (2) Change the column temperature while keeping other conditions unchanged:
[0177] ① Column temperature 25℃; ② Column temperature 35℃
[0178] (3) Change the pH of the mobile phase, while keeping other conditions unchanged:
[0179] ①4.3; ②4.7
[0180] Determination: Take the above solutions respectively and inject them into the liquid chromatograph under different conditions, and record the chromatogram. The data are shown in Table 9 below.
[0181] Table 9 Durability test data
[0182]
[0183]
[0184] It can be seen from the data in the above table that slight changes in column temperature, flow rate and mobile phase will not affect the detection of impurities and the specificity and accuracy of the method, indicating that this method has strong durability.
Claims
1. A method for detecting related substances in alendronate sodium tablets, characterized in that: The following steps are involved: High performance liquid chromatography was used to quantitatively detect the related substances in alendronate sodium tablets; HPLC conditions included: Chromatographic column: Chromatographic column with styrene divinylbenzene copolymer as filler; Mobile phase A: sodium citrate buffer-acetonitrile (75:25, v / v); Mobile phase B: acetonitrile; Flow rate: 1.0ml / min; Column temperature: 30°C; Detection wavelength: 266nm; Diluent: 0.1 mol / L sodium citrate solution.
2. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The elution procedure is as follows:
3. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The related substance is 4-hydroxybenzoic acid.
4. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The preparation method of the reference solution includes: accurately weighing 4-hydroxybenzoic acid and alendronate sodium reference substances, adding 0.1 mol / L sodium citrate solution to dissolve and dilute to prepare a solution containing 3 μg of impurity A and 1.2 μg of alendronic acid per 1 ml, and adding borax solution and acetonitrile respectively; then adding 9-fluorenylmethyl chloroformate acetonitrile solution, shaking for 45 seconds, leaving at room temperature for 30 minutes, then adding dichloromethane, shaking for 60 seconds, centrifuging, and taking the supernatant as the reference solution.
5. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The preparation method of the test solution includes: grinding alendronic acid, adding a solvent, shaking for 30 minutes, ultrasonicating for 5 minutes, cooling, diluting with 0.1 mol / L sodium citrate solution, shaking, filtering, taking the filtrate, adding borax solution and acetonitrile respectively; adding 9-fluorenylmethyl chloroformate acetonitrile solution, shaking for 45 seconds, leaving at room temperature, adding dichloromethane, shaking for 60 seconds, centrifuging, and taking the supernatant as the test solution.
6. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: Record the color spectrum, measure using the external standard method, and calculate the content of known impurities; measure using the main component external standard method and calculate the content of other individual impurities.
7. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The calculation method for known impurities and other individual impurities is: % of known impurities = (impurity peak area in the test sample × concentration of impurities in the reference sample) / (impurity peak area in the reference sample × concentration of alendronic acid in the test sample) × 100%; Other single impurities % = (other single impurity peak area in the test sample × alendronic acid concentration in the reference sample) / (alendronic acid peak area in the reference sample × alendronic acid concentration in the test sample) × 100%.
8. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The mobile phase A is prepared by adding 14.7 g of sodium citrate to 1000 ml of water and adjusting the pH to 4.5 with hydrochloric acid solution.
9. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The injection plate temperature was 5°C.
10. The method for detecting related substances in alendronate sodium tablets according to claim 1, characterized in that: The injection volume was 15 μl.
